Impact of high volume hemofiltration on hemodynamic disturbance and outcome during septic shock

被引:111
作者
Joannes-Boyau, O [1 ]
Rapaport, S [1 ]
Bazin, R [1 ]
Fleureau, C [1 ]
Janvier, G [1 ]
机构
[1] Univ Bordeaux 1, Dept Anesthesiol & Crit care 2, F-33600 Pessac, France
关键词
D O I
10.1097/01.MAT.0000104846.27116.EA
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
The purpose of this study was to evaluate the effect of high volume continuous venovenous hemofiltration (HVCVVH) on hemodynamic and outcome in patients with septic shock. The primary end point was mortality at 28 days. Study design was a prospective case series, and study setting was a 12 bed intensive care unit at a university hospital. A total of 24 consecutive patients with septic shock were included, with dysfunction of more than two organs. All patients were treated by HVCVVH with ultrafiltration rate between 40 ml (.) kg(-1) (.) hr(-1) and 60 ml (.) kg(-1) (.) hr(-1) for 96 hours. In all. patients, the increase in hemodynamic parameters was statistically significant (p < 0.05), with a significant linear decrease in norepinephrine doses (p < 0.05). The predicted 28 day mortality by three different severity scores was more than 70%, and the mortality in the hemofiltration group was 46% (p < 0.075). In the present study of septic shock patients with organ dysfunction, the hemodynamic parameters increased regularly during treatment by HVCVVH. This study suggests a beneficial effect of HVCVVH on 28 day mortality (46% vs. 70%), and further studies with larger cohorts are required.
引用
收藏
页码:102 / 109
页数:8
相关论文
共 36 条
[1]   Strong vasopressor support may be futile in the intensive care unit patient with multiple organ failure [J].
Abid, O ;
Akça, S ;
Haji-Michael, P ;
Vincent, JL .
CRITICAL CARE MEDICINE, 2000, 28 (04) :947-949
[2]   Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock [J].
Annane, D ;
Sébille, V ;
Charpentier, C ;
Bollaert, PE ;
François, B ;
Korach, JM ;
Capellier, G ;
Cohen, Y ;
Azoulay, E ;
Troché, G ;
Chaumet-Riffaut, P ;
Bellissant, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (07) :862-871
[3]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[4]   THE PATHOGENESIS OF SEPSIS [J].
BONE, RC .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (06) :457-469
[6]   PROGNOSTIC VALUES OF TUMOR-NECROSIS-FACTOR CACHECTIN, INTERLEUKIN-1, INTERFERON-ALPHA, AND INTERFERON-GAMMA IN THE SERUM OF PATIENTS WITH SEPTIC SHOCK [J].
CALANDRA, T ;
BAUMGARTNER, JD ;
GRAU, GE ;
WU, MM ;
LAMBERT, PH ;
SCHELLEKENS, J ;
VERHOEF, J ;
GLAUSER, MP .
JOURNAL OF INFECTIOUS DISEASES, 1990, 161 (05) :982-987
[7]   A phase II randomized, controlled trial of continuous hemofiltration in sepsis [J].
Cole, L ;
Bellomo, R ;
Hart, G ;
Journois, D ;
Davenport, P ;
Tipping, P ;
Ronco, C .
CRITICAL CARE MEDICINE, 2002, 30 (01) :100-106
[8]   High-volume haemofiltration in human septic shock [J].
Cole, L ;
Bellomo, R ;
Journois, D ;
Davenport, P ;
Baldwin, I ;
Tipping, P .
INTENSIVE CARE MEDICINE, 2001, 27 (06) :978-986
[9]   Can inflammatory cytokines be removed efficiently by continuous renal replacement therapies? [J].
De Vriese, AS ;
Vanholder, RC ;
Pascual, M ;
Lameire, NH ;
Colardyn, FA .
INTENSIVE CARE MEDICINE, 1999, 25 (09) :903-910
[10]  
DHAINAUT JF, 1998, C ACT SFAR, P339